Introduction: This post-hoc analysis c o m p a r e d t h e e f f e c t s o f s w i t c h i n g t o e z e t i m i b e / s i m v a s t a t i n 1 0 / 2 0 m g (EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) in high-risk hypercholesterolemic patients with/without obesity. Methods: Patients (n=618) at high-risk for coronary heart disease with elevated low-density lipoprotein cholesterol (LDL-C) ≥2.59 and ≤4.92 mmol/L, while on a statin, entered a 6-week openlabel stabilization/screening period during which they continued on the same statin. Patients were then randomized 1:1 to doubleblind EZE/SIMVA 10/20 mg or ROSUVA 10 mg for 6 weeks. Patients were classified as non-obese (n=437) or obese (n=180) based on body mass index <30 or ≥30 kg/m 2 , respectively. Results: EZE/SIMVA was more effective than ROSUVA at lowering LDL-C, total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein (apo) B in the overall population (P<0.001 for all). These results were consistent for obese and non-obese patients as demonstrated by the lack of significant treatment-by-subgroup interaction terms for LDL-C, TC, non-HDL-C, and apo B (P>0.050 for all). Conclusions: In this post-hoc analysis of high-risk patients with elevated LDL-C, despite prior use of statin therapy, switching to EZE/SIMVA 10/20 mg Comb Prod Ther (2011) 1(1):001 versus ROSUVA 10 mg provided superior reductions in LDL-C, TC, and non-HDL-C in obese and non-obese patients.
INTRODUCTION
Obesity has reached global epidemic proportions, and its prevalence continues to increase in many developed countries. Obesity is strongly related to the development of vascular diseases and metabolic complications. 1 and abnormal LDL composition (ie, increased levels of small, dense LDL-C particles). 3, 4 The pathogenesis of the dyslipidemia seen in obese patients is likely due to the state of insulin resistance resulting from the accumulation of excess body fat. 5, 6 As a result, dyslipidemia may be undertreated in patients with obesity even following intensive LDL-C-lowering with statins. To this end, the 2008 American Diabetes Association and American College of Cardiology Foundation (ADA/ACC) consensus report recommends non-HDL-C and apo B treatment targets for managing dyslipidemia in patients with elevated cardiometabolic risk, including obese patients (Table 1) . 7 In view of the need to aggressively manage atherogenic dyslipidemia, the use of combination lipid-lowering therapies may be warranted to facilitate the achievement of optimal lipid and lipoprotein levels. This post-hoc exploratory analysis of data from a previously reported multicenter, randomized, double-blind,
Treatment goals
Level of risk LDL-C 
MATERIALS AND METHODS

Patients and Study Design
Patients were deemed to be of high cardiovascular risk if they met one or more of the following 
Statistical Analyses
Efficacy and safety analyses were conducted in the overall analysis population, as well as within obese and non-obese patient subgroups. Table 2 ). Baseline LDL-C values were generally similar between treatment groups and obesity subgroups.
RESULTS
Patients
Effects of Treatment on Lipid/Lipoprotein
Parameters and hs-CRP
The effects of EZE/SIMVA 10/20 mg and ROSUVA 10 mg on plasma concentrations of Table 2 . Baseline characteristics for randomized obese and non-obese patients.
All data are shown as mean ± SD or n (%), unless otherwise noted. *Excludes one randomized patient in the non-obese group with unknown body mass index at baseline. †Data shown as median ± SD. ‡Two randomized patients had unknown diabetes status at baseline, one is obese on EZE/SIMVA and one is non-obese on ROSUVA. §Low potency stratum: simvastatin 20 mg, pravastatin 40 mg, fluvastatin 80 mg, atorvastatin 10 mg; high potency stratum: simvastatin 40 mg, atorvastatin 20 mg, rosuvastatin 5 mg. Apo B=apolipoprotein B; CHD=coronary heart disease; EZE/SIMVA=ezetimibe/simvastatin combination tablet; FPG=fasting plasma glucose; HDL-C=high-density lipoprotein cholesterol; hs-CRP=high-sensitivity C-reactive protein; LDL-C=low-density lipoprotein cholesterol; ROSUVA=rosuvastatin; SD=standard deviation; T2DM=type 2 diabetes mellitus; TC=total cholesterol; TG=triglyceride.
lipids, lipoproteins, and hs-CRP within the obese and non-obese subgroups are shown in Table 3 . Results for the overall population are provided for comparative purposes. In the overall population, switching from statin monotherapy to EZE/SIMVA 10/20 mg compared with ROSUVA 10 mg for 6 weeks resulted in significantly larger reductions from baseline in LDL-C (10.6%; P<0.001), TC (7.2%; P<0.001), non-HDL-C (9.4%; P<0.001), LDL-C:HDL-C (9.5%; P<0.001), TC:HDL-C (6.2%; P<0.001) and apo B (8.1%: P<0.001) at study endpoint (Table 3 ; Figure 1 ). A borderline significantly greater reduction in TG was seen, favoring EZE/SIMVA therapy (5.1%; P=0.053) ( Table 3 ; Figure 1 ). Both EZE/SIMVA and ROSUVA produced significant increases from baseline in HDL-C; however, the between-group difference did not reach significance. Neither EZE/SIMVA nor ROSUVA produced significant within-or between-group changes from baseline in hs-CRP ( Table 3 ).
The treatment effects within the subgroups were generally consistent with those in the however, the between-group differences did not reach statistical significance (Table 3 ; Table 3) .
Lipid/Lipoprotein Goal Attainment
In the overall population, significantly higher percentages of patients achieved LDL-C levels of <2.59 and <1.81 mmol/L (P<0.001 for both targets; Figure 2 ), non-HDL-C levels of <3.37 and <2.59 mmol/L (P<0.001 for both targets; *Excludes one randomized patient from the EZE/SIMVA group with unknown body mass index at baseline. †Determined by study investigator to be related to the drug. ‡One death that occurred from a traumatic brain injury and subarachnoid hemorrhage was deemed not related to study drug by the investigator. §Includes subjects with two consecutive measurements for ALT and/or AST ≥3× ULN and a single, last measurement ≥3× ULN or a measurement ≥3× ULN followed by a measurement <3× ULN that was taken more than 2 days after the last dose of study medication. ALT=alanine aminotransferase; AST=aspartate aminotransferase; CK=creatine kinase; EZE/SIMVA=ezetimibe/ simvastatin; ROSUVA=rosuvastatin; ULN=upper limit of normal. e treatment by subgroup interaction P-values for non-HDL-C goals <3.37 mmol/L and<2.59 mmol/L were 0.640, and 0.846, respectively. Low plasma HDL-C levels, a characteristic frequently associated with abdominal obesity and insulin resistance, 14, 15 has been shown to be a strong and independent risk factor for future cardiovascular events and mortality. 16 HDL particles are believed to be antiatherogenic by virtue of facilitating cholesterol transport to the liver following efflux from peripheral tissues, and also by exerting antioxidant, antithrombotic, and anti-inflammatory effects. 17, 18 In the current study, treatment with EZE/SIMVA or ROSUVA produced significant increases from baseline in HDL-C, both in the overall study population and non-obese patients; however, neither treatment led to significant improvements in HDL-C within the obese subgroup. The magnitude of the differences, however, was very small and the lack of significant changes from baseline seen with both individual therapies in the obese population may be due to the small number of patients contributing to the analysis.
There were no significant between-treatment differences in HDL-C in the overall population or within either subgroup, indicating that EZE/SIMVA and ROSUVA produced similar effects on HDL-C, irrespective of the patient population examined.
Plasma hs-CRP is an inflammatory biomarker that has been shown to independently predict cardiovascular events and contribute to an individual's global risk classification, irrespective of plasma LDL-C levels. 19 Low grade inflammation, as measured by elevated plasma levels of hs-CRP, is a feature of central obesity. 20 Additionally, hs-CRP has been shown to have deleterious effects on vascular biology. 21 Previous studies suggest that statins lower hs-CRP levels independent of LDL-C. 22, 23 Furthermore, EZE 10 mg administered in combination with statins has been shown to significantly enhance hs-CRP reductions beyond what is seen with statin monotherapy. 24 In the current analysis, 
